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↑ What is "already known" in this topic: {#box1}
========================================

Previous studies confirmed that trastuzumab is effective in improving overall survival of the patients with breast cancer.

→ What this article adds: {#box2}
=========================

The results of new trials were added to this systematic review. The results of the current meta-analysis showed the quantitative effect of trastuzumab in improving overall survival and progression of free survival in patients with breast cancer.

Introduction {#s1}
============

Breast cancer (BC) is the most common type of cancer worldwide and is one of the leading causes of death in cancer patients. Although the rate of BC is decreasing in developed countries, it is rapidly increasing in developing countries ([@R1],[@R2]). Statistics show that every year more than one million new cases of cancer are diagnosed in the world and more than 400 000 people are lost to cancer ([@R3]). Early diagnosis and treatment of BC in its early stages could significantly increase the survival rate of BC patients ([@R4]). Trastuzumab in combination with chemotherapy has been confirmed as the standard treatment of BC for HER2 positive patients ([@R5]). Many studies have found that trastuzumab in combination with chemotherapy prolongs overall survival (OS) ([@R6]) and improves progression-free survival (PFS) ([@R7]). Women with HER2 positive breast cancer are at greater risk for progression of disease and death compared to women who are not HER2 positive ([@R8],[@R9]).

Thus, the purpose of treatment strategies of this type of cancer is blocking HER2 positive BC. Trastuzumab is a recombinant human monoclonal antibody that binds to the chain extracellular protein HER2 and is a key component in treatment of HER2 positive BC in its early stages ([@R10]).

The present study aimed at evaluating the effectiveness of trastuzumab in the treatment of early stage BC.

Methods {#s2}
=======

Literature search {#s2-0-1}
-----------------

A systematic review and meta-analysis was conducted to evaluate the effectiveness of trastuzumab using updated data. PubMed, Cochrane library, Web of Science, Embase, and Google Scholar databases were searched from the beginning to February 2017. The reference list of the selected RCTs and reviews were also searched for additional citations.

Structured questions {#s2-0-2}
--------------------

Our focus was on studies that evaluated the results of treatment in women with early BC. Our interested intervention was trastuzumab as adjuvant therapy in comparison with basic treatment without trastuzumab. Overall survival (OS) and disease- free survival (DFS) were considered as desired outcomes. Randomized controlled trials (RCTs) were the preferred study design. Studies that reported the results of monotherapy of the trastuzumab in BC were excluded. Observational, experimental, and animal studies were also excluded.

All selected studies were saved in Endnote library. After removing duplications, titles and abstracts were screened independently by 2 authors. The disagreements between the 2 authors were resolved by discussion.

Search strategy {#s2-0-3}
---------------

Our search strategy for PubMed is presented as follows:

Breast Neoplasms\[Mesh\]

Breast \[Title/Abstract\] AND (cancer\* \[Title/Abstract\] OR tumour\*\[Title/Abstract\] OR tumor\*\[Title/Abstract\] OR neoplas\*\[Title/Abstract\])

Trastuzumab or Herceptin \[Title/Abstract\]

1 OR 2

3 And 4 Filters: Clinical trial; Humans

Quality appraisal method {#s2-0-4}
------------------------

The quality of the selected studies was evaluated using the Cochrane Risk of Bias Tool and Jadad scale.

Data analysis {#s2-0-5}
-------------

A meta-analysis was conducted to compare the effectiveness of trastuzumab as adjuvant therapy in early stage BC. This analysis was performed using the National Council for Social Studies (NCSS) Version 11 software. Heterogeneity was evaluated using Cochran\`s Q test and I2 criteria. I2 equal to 50% indicated low heterogeneity. Inverse variance method was used to weight the studies.

Results {#s3}
=======

Selection of studies {#s3-0-1}
--------------------

The total of 5 databases were searched and 1818 articles were detected primarily. Following the screening of the titles and abstracts, 87 full text studies were selected. However, only 11 studies met the inclusion criteria ([@R11]-[@R21]), all of which were RCTs. [Figure 1](#F1){ref-type="fig"} demonstrates the preferred reporting items for systematic reviews and meta-analyses (PRISMA) diagram of the selection process.
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Total number of 20 924 patients were included in the selected studies, most of them followed- up the patients for more than 6 months. The summary of the characteristics of the studies are presented in [Table 1](#T1){ref-type="table"}.

###### Study characteristics

  ----- ---------------- ------ --------------------------- -------------- ---------------------------------- -------------
  No.   Study            N      Duration                    Intervention   Comparison                         Jadad scale
  1     B31(10)          394    \>6 months                  Trastuzumab    Without Trastuzumab                2
  2     BCIRG006(11)     1703   \>6 months                  Trastuzumab    Without Trastuzumab                1
  3     Buzdar(12)       42     6 months                    Trastuzumab    Without Trastuzumab                3
  4     Finher(13)       1010   \<6 months                  Trastuzumab    Without Trastuzumab                3
  5     Hera(14)         5081   \>6 months                  Trastuzumab    Without Trastuzumab                3
  6     Noah(15)         235    \>6 months                  Trastuzumab    Without Trastuzumab                3
  7     Pacs-04(16)      528    \>6 months                  Trastuzumab    Without Trastuzumab                1
  8     Goldhirsch(17)   5102   \>6 months                  Trastuzumab    Without Trastuzumab                3
  9     Joensuu(18)      1500   \<6 months and \>6 months   Trastuzumab    Chemotherapy without Trastuzumab   2
  10    Schneider(19)    227    \<6 months and \>6 months   Trastuzumab    1 year or 12 weeks Trastuzumab     3
  11    Gianni(20)       5102   \>6 months                  Trastuzumab    Without trasuzumab                 3
  ----- ---------------- ------ --------------------------- -------------- ---------------------------------- -------------

The OS results {#s3-0-2}
--------------

The results of the Cochran\`s Q test revealed that the homogeneity between selected studies was appropriate (Cochran\`s Q= 12.3437, I2= 0.35%), presented in the Galbraith plot. This plot shows that all studies are placed within the confidence interval of the regression line of Galbraith plot, and thus confirm that the homogeneity of the studies is sufficient. When the homogeneity criterion of the studies was met, the fixed model was used to combine the results of OS ([Fig. 2](#F2){ref-type="fig"}).
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The results of the relative weight of the studies showed that all studies had reported statistically similar effects with nonzero results. The significance level of chi square test was less than 0.05. Moreover, the logarithm of the hazard ratio for \"moderate the impact of\" was less than zero, indicating that the hazard ratio was between 0 and 1 ([Table 2](#T2){ref-type="table"}). Therefore, it is concluded that trastuzumab is effective in increasing patient survival ([Fig. 3](#F3){ref-type="fig"}).

###### The results of the meta-analysis of OS outcome

  ------------------------------ --------------------------------------------- ------------ --------------------- --------
  Study                          Ln(HR)                                        SE(Ln(HR))   Confidence interval   Weight
  B31                            -0.4                                          0.17         (-0.733,-0.067)       8.16
  BCIRG006                       -0.46                                         0.13         (-0.715,-0.205)       13.95
  Finher                         -0.6                                          0.36         (-1.3,0.106)          1.82
  Hera                           -0.46                                         0.17         (-0.793,-0.127)       8.16
  Noah                           -0.48                                         0.3          (-1.07,0.108)         2.62
  Pacs-04                        0.24                                          0.32         (-0.387,0.867)        2.3
  Goldhirsch                     -0.274                                        0.079        (-0.429,-0.120)       37.96
  Schneider                      0.336                                         0.325        (-0.299,0.973)        2.24
  Gianni                         -0.162                                        0.102        (-0.362,0.037)        22.79
  Overall effect                 -0.286                                        0.049        (-0.381,-0.191)       
  Directional Zero-Effect Test   *χ ^2^* =34.689, *df* =1, *P−value* = 0.000                                      
  ------------------------------ --------------------------------------------- ------------ --------------------- --------
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The DFS Results {#s3-0-3}
---------------

The results of the Cochran\`s Q test indicated that homogeneity was not met among the selected studies(Cochran\`s Q= 32.9034, I2= 0.69%). Therefore, the random model was applied to aggregate the results of DFS. [Figure 4](#F4){ref-type="fig"} demonstrates the heterogeneity of DFS within the selected studies with Galbraith plot.
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The results in [Table 3](#T3){ref-type="table"} clarify that the significance level of chi square test was less than 0.05, and thus it is concluded that trastuzumab as adjuvant therapy is effective in improving DFS ([Fig. 5](#F5){ref-type="fig"}).

###### The results of meta-analysis of DFS outcome

  ------------------------------ --------------------------------------- -------------- --------------------- --------
   Study                         *Ln(HR)*                                *SE(Ln(HR))*   Confidence interval   Weight
  B31                            -0.73                                   0.11           (-0.946,-0.514)       12.49
  Bcirg006                       -0.45                                   0.1            (-0.646,-0.254)       13.07
  Buzdar                         -2.27                                   1.11           (-4.44,-0.094)        0.462
  Finher                         -0.87                                   0.35           (-1.56,-0.184)        3.72
  Hera                           -0.46                                   0.09           (-0.636,-0.284)       13.65
  Noah                           -0.53                                   0.22           (-0.961,-0.099)       7.04
  Pacs-04                        -0.15                                   0.18           (-0.503,0.203)        8.72
  Goldhirsch                     -0.274                                  0.07           (-0.412,-0.137)       14.75
  Joensuu                        -0.892                                  0.271          (-1.423,-0.514)       5.51
  Schneider                      0.262                                   0.253          (-0.234,0.758)        5.93
  Gianni                         -0.274                                  0.07           (-0.412,-0.137)       14.75
  Overall effect                 -0.419                                  0.077          (-0.569,-0.269)       
  Directional Zero-Effect Test   χ 2 =116.915, df =1, P −value = 0.000                                        
  ------------------------------ --------------------------------------- -------------- --------------------- --------
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Risk of bias results is presented in [Table 4](#T4){ref-type="table"}.

###### The summary of risk of BIAS results

  ------------ --------------------- ------------------------ -------------------------- ------------------------- -----------------------------
  Study        Sequence generation   Allocation concealment   Blinding of participants   Incomplete outcome data   Selective outcome reporting
  B31          Low                   Unclear                  High                       High                      Unclear
  BCIRG006     Unclear               Unclear                  Unclear                    Unclear                   High
  Buzdar       Low                   Low                      High                       Low                       High
  FinHer       Low                   Low                      High                       Low                       High
  HERA         Low                   Unclear                  High                       Low                       Unclear
  NOAH         Low                   Unclear                  High                       Low                       Low
  PACS-04      Unclear               Unclear                  High                       Low                       Unclear
  Gianni       Low                   Unclear                  High                       Low                       Low
  Goldhirsch   Low                   Unclear                  High                       Low                       Low
  Joensuu      Low                   Unclear                  High                       Low                       Low
  Schneider    Low                   Unclear                  High                       Low                       Low
  ------------ --------------------- ------------------------ -------------------------- ------------------------- -----------------------------

Discussion {#s4}
==========

The present study aimed at evaluating the effectiveness of trastuzumab on OS and DFS as adjuvant therapy in the treatment of early stage BC. The primary results of RCTs revealed that the hazard ratio (HR) of OS in trastuzumab protocol was significantly lower than ordinary chemotherapy. However, Buzdar study reported a HR equal to 1, with no difference between the 2 treatment groups. Maximum HR was reported in Schneider B.P study (HR= 1.4), and minimum HR was related to FinHer study (HR= 0.55).

The primary results of RCTs revealed a significant increase in DFS for trastuzumab adjuvant therapy. Scheneider study, with HR= 1.3, has reported the highest effectiveness rate; and Buzdar study, with HR= 0.103, showed the lowest effectiveness rate for trastuzumab adjuvant therapy. The number of patients in RCTs varied from 42 to 5102.

This meta-analysis was conducted to determine the relative weights of various studies. We combined the HRs and the number of patients in the studies to obtain more accurate and reliable results. We meta-analyzed the OS with 9 RCTs and DFS with 11 RCTs.

Considering the results of the relative weight of the selected studies and HR, Goldhirsch study reported the maximum influence on the OS of the patients, with numerical value of 28.85. The second best results belonged to Luca Gianni study, with the numerical value of 19.37. FinHer study, with the value of 0.999, had the lowest effectiveness in this regard. Buzdar study, with HR= 1, showed that the rate of OS with and without trastuzumab is the same in BC patients.

When analyzing DFS, we found that Luca Gianni and Goldhirsch studies, with the value of 11.21, reported the maximum effectiveness on DFS. The lowest effectiveness was shown in Buzdar study, with the value of 0.047. Thus, it is concluded that trastuzumab is significantly effective in improving DFS.

The most serious side effect of trastuzumab was improvement of congestive heart failure (CHF) ([@R24]), but some studies stated that the risk of CHF for BC patients could be considered zero ([@R26]). Furthermore, the results of studies showed that if cardiac performance is monitored during the treatment time, the damage would not be life- threating and is allowed to continue ([@R24]). Also, it is recommended that trastuzumab be added only to anthracycline-free chemotherapy regimens ([@R25]).

The FinHer study (9 weeks treatment with trastuzumab) demonstrated acceptable and appropriate effectiveness in increasing OS and DFS([@R26]), however, when considering the low relative weight of the study, it is clear that the results would not be confident enough and could not be considered proportional to the total BC population.

In summary, the main findings of this meta-analysis support and update the results of previous studies and confirm that trastuzumab is effective in improving OS and DFS in BC patients. These findings could help healthcare providers to prescribe effective medication for their patients. Likewise, policy makers could use these results as a primary data to provide better coverage for BC patients. Moreover, complementary data would be the results of cost-effectiveness analysis.

Conclusion {#s5}
==========

The addition of trastuzumab as adjuvant therapy in early stages of BC in HER2 positive patients could increase OS and DFS of the patients effectively. The result of FinHer study encourage conducting further studies on this treatment protocol to manage BC.

Recommendations for the future {#s5-0-1}
------------------------------

Considering the shorter treatment period of FinHer study compared to other studies and because of lower costs and lower side effects, it is strongly recommended that larger trials be conducted in this field.
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